Health outcomes and unmet needs in patients with long-standing rheumatoid arthritis attending tertiary care in Greece: a cohort study

Table 4 HAQ results over time according to use of bDMARDs

	Baseline		3 months		6 months		9 months
	Non-bDMARDs	bDMARDs	Non-bDMARDs	bDMARDs	Non-bDMARDs	bDMARDs	Non-bDMARDs	bDMARDs
	N = 86	N = 123	N = 68	N = 115	N = 73	N = 121	N = 78	N = 119
Total HAQ score, mean ± SD	0.68 ± 0.64	0.81 ± 0.63	0.57 ± 0.62	0.75 ± 0.59	0.53 ± 0.54	0.77 ± 0.62	0.54 ± 0.53	0.78 ± 0.62
Adjusted total HAQ score^a, Least-squares mean ± SE	0.67 ± 0.08	0.80 ± 0.07	0.58 ± 0.07	0.75 ± 0.06	0.52 ± 0.07	0.77 ± 0.05	0.58 ± 0.07	0.78 ± 0.05

bDMARD biologic disease-modifying antirheumatic drug, BMI body mass index, HAQ Health Assessment Questionnaire, SD standard deviation, SE standard error
^aHAQ scores adjusted for baseline covariates: age, gender, BMI, and the interaction term of Visit^aBMI

ISSN: 1477-7525